Halozyme Financial Statements (HALO)
|
|
|
|
Report date
|
|
|
23.02.2021 |
22.02.2022 |
31.12.2022 |
21.02.2023 |
20.02.2024 |
|
31.10.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
267.6 |
443.3 |
660.1 |
660.1 |
829.3 |
|
947.4 |
|
Operating Income, bln rub |
|
|
144.3 |
275.9 |
267.5 |
267.5 |
337.6 |
|
477.0 |
|
EBITDA, bln rub |
? |
|
153.0 |
259.0 |
315.5 |
315.5 |
451.9 |
|
570.5 |
|
Net profit, bln rub |
? |
|
129.1 |
402.7 |
202.1 |
202.1 |
281.6 |
|
392.5 |
|
|
OCF, bln rub |
? |
|
55.5 |
299.4 |
240.1 |
240.1 |
388.6 |
|
403.0 |
|
CAPEX, bln rub |
? |
|
2.50 |
1.46 |
4.81 |
4.81 |
15.3 |
|
10.2 |
|
FCF, bln rub |
? |
|
53.0 |
298.0 |
235.3 |
235.3 |
373.3 |
|
392.7 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
13.5 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
3.44% |
|
|
OPEX, bln rub |
|
|
80.0 |
86.0 |
253.3 |
253.3 |
299.3 |
|
247.4 |
|
Cost of production, bln rub |
|
|
43.4 |
81.4 |
139.3 |
139.3 |
192.4 |
|
205.2 |
|
R&D, bln rub |
|
|
34.2 |
35.7 |
66.6 |
66.6 |
76.4 |
|
79.9 |
|
Interest expenses, bln rub |
|
|
20.4 |
7.53 |
16.9 |
16.9 |
18.8 |
|
18.8 |
|
|
Assets, bln rub |
|
|
579.9 |
1 104 |
1 842 |
1 842 |
1 733 |
|
2 118 |
|
Net Assets, bln rub |
? |
|
151.0 |
197.0 |
169.8 |
169.8 |
83.8 |
|
452.7 |
|
Debt, bln rub |
|
|
397.2 |
876.7 |
1 506 |
1 506 |
1 499 |
|
1 504 |
|
Cash, bln rub |
|
|
368.0 |
740.9 |
362.8 |
362.8 |
336.0 |
|
666.3 |
|
Net debt, bln rub |
|
|
29.2 |
135.8 |
1 143 |
1 143 |
1 163 |
|
837.8 |
|
|
Ordinary share price, rub |
|
|
42.7 |
40.2 |
56.9 |
56.9 |
37.0 |
|
34.3 |
|
Number of ordinary shares, mln |
|
|
136.2 |
140.6 |
136.8 |
136.8 |
131.9 |
|
126.9 |
|
|
Market cap, bln rub |
|
|
5 817 |
5 655 |
7 786 |
7 786 |
4 876 |
|
4 351 |
|
EV, bln rub |
? |
|
5 847 |
5 791 |
8 930 |
8 930 |
6 039 |
|
5 189 |
|
Book value, bln rub |
|
|
151 |
197 |
-786 |
-786 |
-806 |
|
-384 |
|
|
EPS, rub |
? |
|
0.95 |
2.86 |
1.48 |
1.48 |
2.13 |
|
3.09 |
|
FCF/share, rub |
|
|
0.39 |
2.12 |
1.72 |
1.72 |
2.83 |
|
3.10 |
|
BV/share, rub |
|
|
1.11 |
1.40 |
-5.74 |
-5.74 |
-6.11 |
|
-3.02 |
|
|
EBITDA margin, % |
? |
|
57.2% |
58.4% |
47.8% |
47.8% |
54.5% |
|
60.2% |
|
Net margin, % |
? |
|
48.2% |
90.8% |
30.6% |
30.6% |
34.0% |
|
41.4% |
|
FCF yield, % |
? |
|
0.91% |
5.27% |
3.02% |
3.02% |
7.66% |
|
9.03% |
|
ROE, % |
? |
|
85.5% |
204.5% |
119.0% |
119.0% |
336.0% |
|
86.7% |
|
ROA, % |
? |
|
22.3% |
36.5% |
11.0% |
11.0% |
16.2% |
|
18.5% |
|
|
P/E |
? |
|
45.1 |
14.0 |
38.5 |
38.5 |
17.3 |
|
11.1 |
|
P/FCF |
|
|
109.9 |
19.0 |
33.1 |
33.1 |
13.1 |
|
11.1 |
|
P/S |
? |
|
21.7 |
12.8 |
11.8 |
11.8 |
5.88 |
|
4.59 |
|
P/BV |
? |
|
38.5 |
28.7 |
-9.91 |
-9.91 |
-6.05 |
|
-11.3 |
|
EV/EBITDA |
? |
|
38.2 |
22.4 |
28.3 |
28.3 |
13.4 |
|
9.10 |
|
Debt/EBITDA |
|
|
0.19 |
0.52 |
3.62 |
3.62 |
2.57 |
|
1.47 |
|
|
R&D/CAPEX, % |
|
|
1 367% |
2 448% |
1 385% |
1 385% |
499.3% |
|
780.7% |
|
|
CAPEX/Revenue, % |
|
|
0.94% |
0.33% |
0.73% |
0.73% |
1.84% |
|
1.08% |
|
| Halozyme shareholders |
